amantadine has been researched along with Dementia Praecox in 46 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 9.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| " The effect of amantadine on neuropsychological function in medicated schizophrenia patients was investigated." | 9.11 | A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. ( Goodman, C; Isakov, V; Knoll, G; Modai, I; Silver, H, 2005) |
| "According to this meta-analysis of 5 RCTs, adjunctive amantadine seems to be an effective option for attenuating antipsychotic-related weight gain in patients with schizophrenia." | 8.95 | Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. ( Gu, YH; Li, M; Ng, CH; Ungvari, GS; Wang, S; Xiang, YQ; Xiang, YT; Yang, XH; Zheng, W, 2017) |
| "To evaluate the potential beneficial effects of amantadine on elderly hospitalized patients with persistent schizophrenia." | 7.76 | Effect of antiviral amantadine treatment on elderly chronic schizophrenia patients. ( Bleich, A; Finkel, B; Goodman, C; Kurs, R; Melamed, Y, 2010) |
| "Amantadine was introduced for the pharmacological management of neuroleptic malignant syndrome (NMS) because of its beneficial effects in Parkinson's disease which were attributed to dopaminomimetic properties." | 7.68 | Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. ( Kornhuber, J; Weller, M, 1993) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 5.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| " The effect of amantadine on neuropsychological function in medicated schizophrenia patients was investigated." | 5.11 | A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. ( Goodman, C; Isakov, V; Knoll, G; Modai, I; Silver, H, 2005) |
| "According to this meta-analysis of 5 RCTs, adjunctive amantadine seems to be an effective option for attenuating antipsychotic-related weight gain in patients with schizophrenia." | 4.95 | Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. ( Gu, YH; Li, M; Ng, CH; Ungvari, GS; Wang, S; Xiang, YQ; Xiang, YT; Yang, XH; Zheng, W, 2017) |
| "This article presents a case of a 14-year-old female twin with schizophrenia who developed severe catatonia following treatment with olanzapine." | 3.79 | A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy. ( Buchmann, J; Häßler, F; Höppner, J; Pohl, B; Reis, O; Weirich, S, 2013) |
| "To evaluate the potential beneficial effects of amantadine on elderly hospitalized patients with persistent schizophrenia." | 3.76 | Effect of antiviral amantadine treatment on elderly chronic schizophrenia patients. ( Bleich, A; Finkel, B; Goodman, C; Kurs, R; Melamed, Y, 2010) |
| " Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)." | 3.75 | Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009) |
| "Amantadine was introduced for the pharmacological management of neuroleptic malignant syndrome (NMS) because of its beneficial effects in Parkinson's disease which were attributed to dopaminomimetic properties." | 3.68 | Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. ( Kornhuber, J; Weller, M, 1993) |
| "Amantadine and biperiden were equally effective in relieving neuroleptic-induced EPS and did not exacerbate TD-type movements." | 2.68 | No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. ( Geraisy, N; Schwartz, M; Silver, H, 1995) |
| "Biperiden treatment was associated with significantly lower scores on Benton Visual Retention Test (P < 0." | 2.68 | Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study. ( Geraisy, N; Silver, H, 1995) |
| "Amantadine was found to be comparable in effect to benztropine mesylate, but with fewer side effects." | 2.64 | A controlled trial of amantadine in drug-induced extrapyramidal disorders. ( Bernardo, DL; DiMascio, A; Greenblatt, DJ; Marder, JE, 1976) |
| "Tardive Tourette syndrome is an extrapyramidal symptom which appears after long-term neuroleptic use." | 2.43 | [Two cases of tardive Tourette syndrome]. ( Ohmori, T; Yamauchi, K, 2006) |
| "Amantadine hydrochloride is an antiviral medication used as therapy for parkinsonism and as a cognitive enhancer." | 1.35 | Cardiotoxicity after massive amantadine overdose. ( Kazzi, Z; Morgan, B; Patel, M; Schwartz, M, 2008) |
| " The dosage was increased to 300 mg on September 18 because there was no improvement and no side effects." | 1.31 | Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient. ( Kojima, T; Matsushima, E; Matsuura, M; Ohta, K; Toru, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (45.65) | 18.7374 |
| 1990's | 9 (19.57) | 18.2507 |
| 2000's | 7 (15.22) | 29.6817 |
| 2010's | 9 (19.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, W | 1 |
| Wang, S | 1 |
| Ungvari, GS | 1 |
| Ng, CH | 1 |
| Yang, XH | 1 |
| Gu, YH | 1 |
| Li, M | 1 |
| Xiang, YQ | 1 |
| Xiang, YT | 1 |
| Chen, CW | 1 |
| Lin, SH | 1 |
| Huang, LC | 1 |
| Yang, YK | 1 |
| Ene-Stroescu, V | 1 |
| Nguyen, T | 1 |
| Waiblinger, BE | 1 |
| Czepielewski, LS | 1 |
| Sodré, L | 1 |
| Souza, AC | 1 |
| Bücker, J | 1 |
| Burke, KP | 1 |
| Ceresér, KM | 1 |
| Gama, CS | 3 |
| Schwartz, M | 2 |
| Patel, M | 1 |
| Kazzi, Z | 1 |
| Morgan, B | 1 |
| Stauffer, VL | 1 |
| Lipkovich, I | 1 |
| Hoffmann, VP | 2 |
| Heinloth, AN | 1 |
| McGregor, HS | 1 |
| Kinon, BJ | 1 |
| Lucena, DD | 1 |
| Cruz, C | 1 |
| Lobato, MI | 1 |
| Belmonte-de-Abreu, PS | 1 |
| Finkel, B | 1 |
| Goodman, C | 2 |
| Melamed, Y | 1 |
| Kurs, R | 1 |
| Bleich, A | 1 |
| Case, M | 1 |
| Jacobson, JG | 1 |
| de Lucena, DF | 1 |
| Pinto, JP | 1 |
| Hallak, JE | 1 |
| Crippa, JA | 1 |
| Häßler, F | 1 |
| Reis, O | 1 |
| Weirich, S | 1 |
| Höppner, J | 1 |
| Pohl, B | 1 |
| Buchmann, J | 1 |
| Ohta, K | 1 |
| Matsushima, E | 1 |
| Matsuura, M | 1 |
| Toru, M | 1 |
| Kojima, T | 1 |
| Bahk, WM | 1 |
| Lee, KU | 1 |
| Chae, JH | 1 |
| Pae, CU | 1 |
| Jun, T | 1 |
| Kim, KS | 1 |
| Graham, KA | 1 |
| Gu, H | 1 |
| Lieberman, JA | 1 |
| Harp, JB | 1 |
| Perkins, DO | 1 |
| Silver, H | 4 |
| Isakov, V | 1 |
| Knoll, G | 1 |
| Modai, I | 1 |
| Yamauchi, K | 1 |
| Ohmori, T | 1 |
| Tegeler, J | 1 |
| Wöller, W | 1 |
| Borison, RL | 1 |
| Allen, RM | 1 |
| Gangadhar, BN | 1 |
| Desai, NG | 1 |
| Channabasavanna, SM | 1 |
| Saito, M | 1 |
| Kita, S | 1 |
| Kagono, Y | 1 |
| Suitsu, N | 1 |
| Honda, Y | 1 |
| Geraisy, N | 3 |
| Kornhuber, J | 1 |
| Weller, M | 1 |
| König, P | 1 |
| Chwatal, K | 1 |
| Havelec, L | 1 |
| Riedl, F | 1 |
| Schubert, H | 1 |
| Schultes, H | 1 |
| Yamada, K | 1 |
| Kanba, S | 1 |
| Ohnishi, K | 1 |
| Ashikari, I | 1 |
| Yagi, G | 1 |
| Asai, M | 1 |
| Levine, J | 1 |
| Martine, T | 1 |
| Feraro, R | 1 |
| Kimhi, R | 1 |
| Bracha, HS | 1 |
| DiMascio, A | 1 |
| Bernardo, DL | 1 |
| Greenblatt, DJ | 1 |
| Marder, JE | 1 |
| González, ER | 1 |
| Gelenberg, AJ | 1 |
| Mandel, MR | 1 |
| Sczesni, B | 1 |
| Becker, H | 1 |
| Schröder, J | 1 |
| Bittkau, S | 1 |
| von Baumgarten, F | 1 |
| Truong, DD | 1 |
| Przuntek, H | 1 |
| Lindenmayer, JP | 1 |
| Vakharia, M | 1 |
| Kanofsky, D | 1 |
| Nestelbaum, Z | 1 |
| Siris, SG | 1 |
| Rifkin, A | 1 |
| Klar, H | 1 |
| Reardon, GT | 1 |
| Hitri, A | 2 |
| Craft, RB | 2 |
| Fallon, J | 1 |
| Sethi, R | 2 |
| Sinha, D | 2 |
| McEvoy, JP | 1 |
| McCue, M | 1 |
| Freter, S | 1 |
| Fayen, M | 1 |
| Goldman, MB | 1 |
| Moulthrop, MA | 1 |
| Luchins, DJ | 1 |
| Cook, PE | 1 |
| Dermer, SW | 1 |
| McGurk, T | 1 |
| Lazarus, A | 1 |
| Kamianov, IM | 1 |
| Kupisk, AG | 1 |
| Katsen, IZ | 1 |
| Rappaport, M | 1 |
| Balunov, OA | 1 |
| Bazhin, EF | 1 |
| Morozova, ES | 1 |
| Fedotenkova, TN | 1 |
| Mindham, RH | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Kelly, JT | 1 |
| Zimmermann, RL | 1 |
| Abuzzahab, FS | 1 |
| Schiele, BC | 1 |
| Decker, BL | 1 |
| Davis, JM | 1 |
| Jonowsky, DS | 1 |
| el-Yousef, MK | 1 |
| Sekerke, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973] | Phase 3 | 199 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Olanzapine | 2.76 |
| Olanzapine + Amantadine | 2.40 |
| Olanzapine + Metformin | 0.65 |
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 48.24 | -13.89 |
| Olanzapine + Amantadine | 45.90 | -9.90 |
| Olanzapine + Metformin | 47.00 | -9.72 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 4.06 | -0.98 |
| Olanzapine + Amantadine | 4.03 | -0.72 |
| Olanzapine + Metformin | 4.00 | -0.79 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 12.76 | -6.39 |
| Olanzapine + Amantadine | 14.22 | -4.12 |
| Olanzapine + Metformin | 15.40 | -4.36 |
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | correlation (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| EI: Disinhibition | EI: Cognitive Restraint | EI: Hunger | FCI: Carbohydrates/Starches (N=186, N=141) | FCI: Fast Food Fats (N=188, N=140) | FCI: High Fats (N=186, N=138) | FCI: Sweets (N=187, N=140) | FCI: Total Score (N=184, N=137) | |
| 2 Weeks | -0.034 | -0.273 | -0.150 | 0.013 | -0.019 | 0.051 | 0.022 | 0.039 |
| 22 Weeks | 0.285 | -0.038 | 0.148 | -0.064 | 0.047 | 0.043 | -0.008 | -0.000 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.32 | 0.26 |
| Olanzapine + Amantadine | 5.25 | 0.10 |
| Olanzapine + Metformin | 5.28 | 0.01 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.25 | -0.00 |
| Olanzapine + Amantadine | 1.26 | -0.11 |
| Olanzapine + Metformin | 1.22 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 3.02 | 0.16 |
| Olanzapine + Amantadine | 3.06 | -0.04 |
| Olanzapine + Metformin | 2.91 | -0.02 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.01 | 0.36 |
| Olanzapine + Amantadine | 5.03 | 0.01 |
| Olanzapine + Metformin | 4.91 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.58 | 0.33 |
| Olanzapine + Amantadine | 1.61 | 0.35 |
| Olanzapine + Metformin | 1.68 | 0.06 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | percent hemoglobin A1c (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.51 | 0.09 |
| Olanzapine + Amantadine | 5.48 | 0.10 |
| Olanzapine + Metformin | 5.53 | -0.03 |
2 reviews available for amantadine and Dementia Praecox
| Article | Year |
|---|---|
Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Amantadine; Antipsychotic Agents; Dopamine Agents; Drug Therapy, Combination; Drug-Related Side Effe | 2017 |
[Two cases of tardive Tourette syndrome].
Topics: Adult; Akathisia, Drug-Induced; Alcoholism; Amantadine; Antipsychotic Agents; Cholinergic Antagonist | 2006 |
15 trials available for amantadine and Dementia Praecox
| Article | Year |
|---|---|
Changes in verbal learning of patients with schizophrenia: Results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics.
Topics: Adult; Amantadine; Antipsychotic Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combina | 2015 |
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro | 2012 |
Open label study of the effect of amantadine on weight gain induced by olanzapine.
Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body We | 2004 |
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
Topics: Amantadine; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dopamine Agents; Double-Blind Me | 2005 |
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients.
Topics: Adult; Amantadine; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Female; Huma | 2005 |
No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Antipsychotic Agents; Biperiden; Cross-Over Studies; Double-Blind Method; Dyskine | 1995 |
Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study.
Topics: Adult; Amantadine; Biperiden; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Memory; | 1995 |
No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Biperiden; Chronic Disease; Cross-Over Studies; Dopamine | 1995 |
Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders.
Topics: Amantadine; Biperiden; Double-Blind Method; Female; Humans; Male; Movement Disorders; Schizophrenia; | 1996 |
A controlled trial of amantadine in drug-induced extrapyramidal disorders.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dru | 1976 |
Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients.
Topics: Adult; Amantadine; Antipsychotic Agents; Benztropine; Drug Interactions; Humans; Male; Memory; Middl | 1987 |
Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
Topics: Adult; Amantadine; Antipsychotic Agents; Benztropine; Chronic Disease; Dyskinesia, Drug-Induced; Fem | 1987 |
Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.
Topics: Adult; Amantadine; Antipsychotic Agents; Cerebral Ventricles; Clinical Trials as Topic; Dilatation, | 1988 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Benztropine; Capsules; Chlorpromazine; Clini | 1974 |
29 other studies available for amantadine and Dementia Praecox
| Article | Year |
|---|---|
Transcranial direct current stimulation (tDCS) improved psychomotor slowness and decreased catatonia in a patient with schizophrenia: Case report.
Topics: Adult; Amantadine; Antipsychotic Agents; Bupropion; Catatonia; Female; Flupenthixol; Humans; Psychom | 2018 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato | 2014 |
Cardiotoxicity after massive amantadine overdose.
Topics: Adult; Amantadine; Antiparkinson Agents; Arrhythmias, Cardiac; Blood Gas Analysis; Blood Pressure; C | 2008 |
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.
Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D | 2009 |
Improvement of schizophrenia negative and positive symptoms with amantadine as add-on therapy to antipsychotics: a case series.
Topics: Amantadine; Antipsychotic Agents; Clinical Trials as Topic; Humans; Nootropic Agents; Randomized Con | 2010 |
Effect of antiviral amantadine treatment on elderly chronic schizophrenia patients.
Topics: Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cognition; Cohort Studies; Female; Geriatric | 2010 |
Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder.
Topics: Adult; Amantadine; Catatonia; Female; Humans; Male; Psychotic Disorders; Receptors, N-Methyl-D-Aspar | 2012 |
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Comb | 2013 |
Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient.
Topics: Amantadine; Brain; Dopamine Agents; Electroencephalography; Epilepsy, Generalized; Female; Humans; M | 2000 |
[Therapeutic measures in tardive dyskinesia].
Topics: Age Factors; Amantadine; Antipsychotic Agents; Baclofen; Benzodiazepines; Bromocriptine; Deanol; Dih | 1983 |
Amantadine in the management of extrapyramidal side effects.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Humans | 1983 |
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Topics: Adult; Aged; Amantadine; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Drug Ther | 1982 |
Amantadine in the neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome | 1984 |
Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients.
Topics: Adolescent; Amantadine; Brain; Computers; Electroencephalography; Female; Glycolates; Haloperidol; H | 1982 |
Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Antipsychotic Agents; Depressive Disorder; Female; Glutamates; Glutamic Acid; Hum | 1993 |
Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Topics: Adult; Aged; Amantadine; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Ad | 1997 |
Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry.
Topics: Adult; Amantadine; Antipsychotic Agents; Chronic Disease; Dominance, Cerebral; Dopamine Agents; Fema | 1997 |
For mental patients, the 'cure' may be worse.
Topics: Amantadine; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Risk; Schizophrenia | 1979 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Ha | 1977 |
[Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases].
Topics: Adult; Amantadine; Antipsychotic Agents; Bromocriptine; Dantrolene; Depressive Disorder; Diazepam; D | 1991 |
Fluoxetine in chronic schizophrenia.
Topics: Amantadine; Chronic Disease; Drug Therapy, Combination; Fluoxetine; Humans; Loxapine; Male; Middle A | 1990 |
Exacerbation of schizophrenia associated with amantadine.
Topics: Acute Disease; Adult; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Drug Therapy, Combin | 1986 |
Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; | 1987 |
Fatal overdose with amantadine.
Topics: Adult; Amantadine; Drug Therapy, Combination; Flupenthixol; Humans; Male; Schizophrenia; Schizophren | 1986 |
Neuroleptic malignant syndrome and amantadine withdrawal.
Topics: Acute Disease; Amantadine; Basal Ganglia Diseases; Female; Humans; Middle Aged; Neuroleptic Malignan | 1985 |
[Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Catatonia; Chlorpromazine; Facial Mus | 1973 |
Mental health research at a state hospital. An attempt at a balanced program.
Topics: Amantadine; Attitude of Health Personnel; Auditory Perception; Behavior Therapy; Computers; Conditio | 1968 |
[Use of the Soviet preparation midantan in the treatment of the Parkinsonian syndrome].
Topics: Adult; Aged; Amantadine; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle | 1974 |
Amantadine hydrochloride treatment of tardive dyskinesia.
Topics: Amantadine; Female; Humans; Movement Disorders; Schizophrenia | 1971 |